Closure of Secundum Atrial Septal Defects With the AMPLATZER Septal Occluder: A Prospective, Multicenter, Post-Approval Study

Daniel R Turner, Carl Y Owada, Charlie J Sang Jr, Muhammad Khan, D Scott Lim, Daniel R Turner, Carl Y Owada, Charlie J Sang Jr, Muhammad Khan, D Scott Lim

Abstract

Background: Prospective data on the medium-term safety and effectiveness of the AMPLATZER Septal Occluder in clinical practice are not available. The objective of this study was to prospectively evaluate the risk of hemodynamic compromise and obtain medium-term survival data on patients implanted with the AMPLATZER Septal Occluder for percutaneous closure of secundum atrial septal defects.

Methods and results: Subjects were enrolled prospectively at 50 US sites and followed for 2 years. Between 2008 and 2012, atrial septal defect closure with the AMPLATZER Septal Occluder was attempted in 1000 patients (aged 0.3-83.6 years, mean 21±22 years). Procedural closure occurred in 97.9%, with 1-month and 2-year closure 98.5% and 97.9%, respectively. Hemodynamic compromise occurred in 6 subjects (0.65%), because of dysrhythmia in 2, device embolization in 1, and cardiac erosion in 3. The rate of cardiac erosion was 0.3% (average 83, range 12-171 days from implant).

Conclusions: Closure of atrial septal defect with the AMPLATZER Septal Occluder is safe and effective. The rate of hemodynamic compromise and cardiac erosion is rare. The risk factors for cardiac erosion after device closure are not yet clear.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00650936.

Keywords: catheterization; echocardiography; heart; heart septal defects; risk factors.

© 2017 The Authors.

Figures

Figure.
Figure.
Subject flow diagram.

References

    1. Crawford GB, Brindis RG, Krucoff MW, Mansalis BP, Carroll JD. Percutaneous atrial septal occluder devices and cardiac erosion: a review of the literature. Catheter Cardiovasc Interv. 2012;80:157–167. doi: 10.1002/ccd.24347.
    1. Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand WE, Kleinman CS. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv. 2004;63:496–502. doi: 10.1002/ccd.20211.
    1. Amin Z. Echocardiographic predictors of cardiac erosion after Amplatzer septal occluder placement. Catheter Cardiovasc Interv. 2014;83:84–92. doi: 10.1002/ccd.25175.
    1. US Food and Drug Administration. Rare serious erosion events associated with St. Jude AMPLATZER™ atrial septal occluder (ASO): FDA safety communication. 2013. .
    1. Roberts WT, Parmar J, Rajathurai T. Very late erosion of Amplatzer septal occluder device presenting as pericardial pain and effusion 8 years after placement. Catheter Cardiovasc Interv. 2013;82:E592–E594. doi: 10.1002/ccd.24755.
    1. Diab K, Kenny D, Hijazi ZM. Erosions, erosions, and erosions! Device closure of atrial septal defects: how safe is safe? Catheter Cardiovasc Interv. 2012;80:168–174. doi: 10.1002/ccd.24517.
    1. Kouchoukos NT, Blackstone EH, Hanley FL, Kirklin JK. Kirklin/Barratt-Boyes Cardiac Surgery. 4th ed. Elsevier Health Sciences; 2013. Atrial septal defect and partial anomalous pulmonary venous connection. pp. 1157–1163.
    1. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP, Jr, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD, Smith SC, Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Page RL, Riegel B, Tarkington LG, Yancy CW American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease); American Society of Echocardiography; Heart Rhythm Society; International Society for Adult Congenital Heart Disease; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52:e143–e263. doi: 10.1016/j.jacc.2008.10.001.
    1. Webb G, Gatzoulis MA. Atrial septal defects in the adult: recent progress and overview. Circulation. 2006;114:1645–1653. doi: 10.1161/CIRCULATIONAHA.105.592055.
    1. Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Larntz K Amplatzer Investigators. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J Am Coll Cardiol. 2002;39:1836–1844. doi: 10.1016/S0735-1097(02)01862-4.
    1. Butera G, Biondi-Zoccai G, Sangiorgi G, Abella R, Giamberti A, Bussadori C, Sheiban I, Saliba Z, Santoro T, Pelissero G, Carminati M, Frigiola A. Percutaneous versus surgical closure of secundum atrial septal defects: a systematic review and meta-analysis of currently available clinical evidence. EuroIntervention. 2011;7:377–385. doi: 10.4244/EIJV7I3A63.
    1. Kutty S, Hazeem AA, Brown K, Danford CJ, Worley SE, Delaney JW, Danford DA, Latson LA. Long-term (5- to 20-year) outcomes after transcatheter or surgical treatment of hemodynamically significant isolated secundum atrial septal defect. Am J Cardiol. 2012;109:1348–1352. doi: 10.1016/j.amjcard.2011.12.031.
    1. DiBardino DJ, McElhinney DB, Kaza AK, Mayer JE., Jr. Analysis of the US Food and Drug Administration Manufacturer and User Facility Device Experience database for adverse events involving Amplatzer septal occluder devices and comparison with the Society of Thoracic Surgery congenital cardiac surgery database. J Thorac Cardiovasc Surg. 2009;137:1334–1341. doi: 10.1016/j.jtcvs.2009.02.032.
    1. Karamlou T, Diggs BS, Ungerleider RM, McCrindle BW, Welke KF. The rush to atrial septal defect closure: is the introduction of percutaneous closure driving utilization? Ann Thorac Surg. 2008;86:1584–1590. discussion 1590. doi: 10.1016/j.athoracsur.2008.06.079.
    1. Ooi YK, Kelleman M, Ehrlich A, Glanville M, Porter A, Kim D, Kogon B, Oster ME. Transcatheter versus surgical closure of atrial septal defects in children: a value comparison. JACC Cardiovasc Interv. 2016;9:79–86. doi: 10.1016/j.jcin.2015.09.028.
    1. McElhinney DB, Quartermain MD, Kenny D, Alboliras E, Amin Z. Relative risk factors for cardiac erosion following transcatheter closure of atrial septal defects: a case-control study. Circulation. 2016;133:1738–1746. doi: 10.1161/CIRCULATIONAHA.115.019987.
    1. O’Byrne ML, Glatz AC, Sunderji S, Mathew AE, Goldberg DJ, Dori Y, Rome JJ, Gillespie MJ. Prevalence of deficient retro-aortic rim and its effects on outcomes in device closure of atrial septal defects. Pediatr Cardiol. 2014;35:1181–1190. doi: 10.1007/s00246-014-0914-6.
    1. Podnar T, Martanovic P, Gavora P, Masura J. Morphological variations of secundum-type atrial septal defects: feasibility for percutaneous closure using Amplatzer septal occluders. Catheter Cardiovasc Interv. 2001;53:386–391. doi: 10.1002/ccd.1187.
    1. O’Byrne ML, Gillespie MJ, Kennedy KF, Dori Y, Rome JJ, Glatz AC. The influence of deficient retro-aortic rim on technical success and early adverse events following device closure of secundum atrial septal defects: an Analysis of the IMPACT Registry(®). Catheter Cardiovasc Interv. 2017;89:102–111. doi: 10.1002/ccd.26585.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する